PlasmaxTM is a cell culture medium that closely mimics the metabolic and physiological profile of human plasma. It is a chemically defined and ready-to-use medium, painstakingly developed to give the best possible representation of in vivo conditions.
Dr. Tardito, an oncometabolism researcher at the Cancer Research UK Beatson Institute, observed that growth focussed media can have a range of effects on cellular metabolism that is cell-type and condition specific (e.g. normoxia/ hypoxia). This effects the experimental results obtained. Dr. Tardito sought to develop a human plasma like cell culture medium that represents the in vivo cellular environment by providing a physiological complement of nutrients provided by human plasma - PlasmaxTM. Find out more about PlasmaxTM
Growth focussed media lack a number of key components that are present in human plasma like media such as PlasmaxTM . PlasmaxTM contains over 80 components, of which 50 have been optimised to the levels found within human plasma, providing a more comprehensive and physiologically relevant nutritional profile.
Yes, PlasmaxTM is ready-to-use and is designed to be used as a direct replacement for conventional media. Cell viability has been tested in various cell types with 2.5% Foetal Bovine Serum.
Unlike growth-focussed media, PlasmaxTM is designed to mimic the nutrient profile of human plasma, better reflecting the cancer microenvironment and providing more physiologically accurate experimental results. Growing cells in PlasmaxTM results in a metabolite profile that is statistically similar to in vivo tumours.
PlasmaxTM is the only ready-to-use cell culture medium containing growth enhancing components at physiological levels as well as essential trace elements. These trace elements are essential as they:
PlasmaxTM has been used to successfully culture a number of cell lines including:
Cell type | Tissue of origin | Cells status | Species |
---|---|---|---|
HepG2 | Liver cancer | Established line | Human |
HuH7 | Liver cancer | Established line | Human |
HuH6 | Liver cancer | Established line | Human |
BT549 | Breast cancer | Established line | Human |
MDA-MB-468 | Breast cancer | Established line | Human |
Cal120 | Breast cancer | Established line | Human |
A375 | Melanoma | Established line | Human |
Colo829 | Melanoma | Established line | Human |
LN18 | Brain cancer | Established line | Human |
Naive glioblastoma cells | Brain cancer | Low passage lines | Human |
Dermal Fibroblasts | Epidermis | Primary | Human |
Small intestin organoid | Small intestine | Primary | Mouse |
Mammosphers | Mammary gland | Primary | Mouse |
Mesenchimal stromal cells | Bone marrow | Primary | Human |
Embryonic stem cells | Embryo | Primary | Human |
Trophoblast stem cells | Placenta | Primary | Human |
Since its composition reflects that of human plasma, it should be suitable for many other cell types.
If you have specific cells you wish to use PlasmaxTM on, or would like further details on the cell lines mentioned above, we are happy to answer your question in more detail. Please contact us.
PlasmaxTM can be supplemented with antibiotics. The inventors have supplemented Plasmax with penicillin-streptomycin to grow primary cells without issues. They do not have direct experience with Primocin (proprietary components) but do not anticipate any problem by supplementing it to Plasmax.
PlasmaxTM does not contain any proteins, growth factors or lipid therefore FBS should be added at the concentration you consider most appropriate. The range is from 0% (+ growth factors and albumax) to 10% depending on the cell type and experiment. The use of dyalized FBS reduces the contribution of metabolites at unknown concentrations, minimizing the divergence from the original Plasmax formulation. We would recommend dialyzed FBS for the experiments where the concentration of specific nutrients is critical.
CancerTools.org is the research tools arm of Cancer Research UK, a registered charity in England and Wales (1089464), Scotland (SCO41666), the Isle of Man (1103) and Jersey (247).